CD19 and leukemia: Furthermore, directing a CD19-specific CAR specifically to the T-cell receptor α constant (TRAC) locus results in enhanced T-cell potency, with edited cells vastly outperforming conventionally generated CAR T cells in preclinical leukemia models [76] (Figure 2).